Nivolumab – MD Update

Cancer Care Gastroenterology Internal Systems Special Section

Hemophilia, Hodgkin’s Disease, and Multiple Myeloma

October 1, 2016July 17, 2017 Bob Baker absence of a clot factor, ARNP, B., bleed disorder hemophilia, blood cancer, blood product, cancer, clinic, clinic 's director, complication, condition day, coordinate effort of nurse practitioner, Croley, current research, cytotoxic, development of long-acting factor replacement, disorder, disorder hemophilia, effective treatment, extended team, extended team of physiotherapist, factor replacement, factor replacement regimen, good prophylactic factor replacement regimen, hematologist, hematology, hemophilia, hemophilia B., hemophilia case, hemophilia clinic, hemophilia foundation, hemophilia patient, hepatitis, Hodgkin, Hodgkin 's disease, human blood product, human genetic engineer, infusion, James Graham Brown, James Graham Brown cancer center, Jessica Croley, KentuckyOne, KentuckyOne health, KentuckyOne health center, KentuckyOne health hemophilia clinic, Lexington, Lexington bleed disorder, Lexington focus, long-acting, long-acting factor replacement, Louisville, major direction, major direction of current research, medical oncologist, multidisciplinary treatment, Multimodality, Multimodality hemophilia clinic, multiple myeloma, myeloma, national hemophilia foundation, Nivolumab, oncologist, oncology fellowship, Patricia Ashby, R., regimen, replacement, Sharma, significant population of patient, special interest, specific treatment protocol, T, T cell, therapy, treat bleed disorder, treatment of hemophilia, U, Vivek, Vivek R.

LOUISVILLE & LEXINGTON Bleeding disorders and blood cancers are two areas in medicine where the dreams of a few years

Read more

Cancer Care Cover Story

A Transformative Moment in Cancer Care

November 1, 2015July 17, 2017 Jennifer S. Newton BRCA1, BRCA2, breast, breast cancer, breath, breath test, brown cancer center, Brown cancer center director, cancer, cancer care, cancer center, cancer center location, cancer morbidity, cancer patient, cancer service, cancer treatment, cancer type, cancer-related, cancer-related death, checkpoint, checkpoint inhibitor, chemotherapy, Chesney, clinic, clinical operation, clinical trial, colon, CT, CT scan, deputy director, deputy director of the brown cancer center, detection, director of clinical operation, director of the breast cancer, director of the lung cancer, downtown location, expertise, FACP, gene, genetic test, identified gene, immune checkpoint inhibitor, immune system, inhibitor, James Graham Brown, James Graham Brown cancer center, Jewish northeast, Kentuckian, Kentucky, KentuckyOne, KentuckyOne health, Kloecker, liver, Louisville, lung, lung cancer, lung cancer patient, mammography, medical center, medical oncologist, melanoma, Milburn, Miller, mortality, multidisciplinary care, multidisciplinary clinic, multiple cancer type, Nivolumab, northeast, northeast location, novel therapy, oncologist, oncology, oncology service, oncolytic, oncolytic virus, PALB2, PD-1, PD-1 inhibitor, pembrolizumab, pharmacy, photograph, physician, provider, radiation, radiation oncologist, referral, Riley, scan, specialty, specialty pharmacy, stage 4, strong family history, synergy, therapy, transformative moment, tumor, U, vice president of oncology service, virus

LOUISVILLE The James Graham Brown Cancer Center has a long and successful history in Louisville and the region. According to

Read more

Cancer Care Cover Story Oncology

Game Changer

July 1, 2014July 17, 2017 Jennifer S. Newton 30 to 40 % response rate, A., antibody, autoimmune, Bristol-Myers Squibb, broad clinical trial program, brown cancer center, cancer, cancer center, cancer patient, carcinoma, cell carcinoma, changer, checkpoint, checkpoint protein, Chesney, clinical trial, clinical trial center, community oncology center, CTLA-4, dose-escalation, Dr. Jason Chesney, early access, FDA, FDA approval, FDA-approved, FDA-approved drug, game changer, health care access, immune checkpoint protein, immune system, immunotherapy, imperative message, improvement, infusion, inhibitor, ipilimumab, Ipilimumab work, James Graham Brown, James Graham Brown cancer center deputy director, Jason A., Kentucky, KentuckyOne, KentuckyOne health, Louisville university, Louisville university of Louisville 's, lung, lung cancer, melanoma, melanoma patient, Merck, new class, new class of drug, Nivolumab, oncology, overall survival, patient access, PD-1, PD-1 inhibitor, PD-L1, pembrolizumab, PFK-158, phase 1/2, phase 1/2 dose-escalation trial, pretty compel, protein, renal cell carcinoma, response rate, stage 4, stage 4 cancer, stage 4 melanoma, stage 4 melanoma patient, standard FDA-approved drug, survival, survival data, survival rate, therapy, trial center, tumor, U, Yervoy®

LOUISVILLE University of Louisville’s (U of L) James Graham Brown Cancer Center Deputy Director Jason A. Chesney, MD, PhD, has

Read more